Results 241 to 250 of about 4,183,748 (324)

Mass mutation in Oenothera pratincola [PDF]

, 1919
Klebahn
openalex   +1 more source

Comprehensive analysis of a novel LYST mutation in a Tunisian patient with Chediak-Higashi syndrome. [PDF]

BMC Med Genomics
Amri Y, Chouchene S, Foddha H, Abderahmene A, Kooli I, Toumi A, Hadj Khalifa K, Mezrigui R, Messaoud T, Hassine M, Dabboubi R.   +10 more
europepmc   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

HEREDITY AND MUTATION AS CELL PHENOMENA

, 1915
R. Ruggles Gates
openalex   +2 more sources

PHOTOREACTIVATION OF ULTRAVIOLET-IRRADIATED ESCHERICHIA COLI, WITH SPECIAL REFERENCE TO THE DOSE-REDUCTION PRINCIPLE AND TO ULTRAVIOLET-INDUCED MUTATION [PDF]

, 1949
Albert Kelner
openalex   +1 more source

Prognostic Factors in EGFR Mutation-positive Patients With Bone Metastases from Lung Adenocarcinoma. [PDF]

Cancer Diagn Progn
Osaka S, Kawashima J, Kaguchi R, Toda N, Kisohara A, Kan S, Tagawa K, Kojima T, Nagai T, Osaka E, Nakanishi K, Tanaka Y.   +11 more
europepmc   +1 more source

Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma

Molecular Oncology, EarlyView.
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski, Molly R. Danks, John P. Thomson, Morwenna Muir, Martin Lee, John C. Dawson, Ana T. Amaral, Juan Diaz‐Martin, David S. Moura, Javier Martin‐Broto, Ali Alsaadi, Donald M. Salter, Ailsa J. Oswald, Graeme Grimes, Larry Hayward, Ted R. Hupp, Karen Sisley, Paul H. Huang, Neil O. Carragher, Valerie G. Brunton   +19 more
wiley   +1 more source

Langerhans Cell Histiocytosis With <i>MAP2K1^E102_I103del</i> Mutation Successfully Treated With Trametinib. [PDF]

EJHaem
Lang M, Chang L, Cao XX.
europepmc   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

A novel mouse model for X-linked Alport syndrome induced by splicing mutation in the Col4a5 gene. [PDF]

Sci Rep
Ye Z, Lu D, Zhou S, Li G, Long L, Zhang J, Liu M, Gao X.   +7 more
europepmc   +1 more source